Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-7

  Krishnamurthy, Savitri ^a   Woodward, Wendy ^a   Yang, Wei ^a   Reuben, James M ^a   Tepperberg, James ^b   Ogura, Dai ^c   Niwa, Shin Ichiro ^c   Huo, Lei ^a   Gong, Yun ^a   El Zein, Randa ^a   Gonzalez Angulo, Ana M ^a   Gregor, Mariana Chavez Mac ^a   Alvarez, Ricardo ^a   Lucci, Anthony ^a   Valero, Vicente ^a   Ueno, Naoto T ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

^c Link Genomics ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887311817     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-409     Document Type: Article

References (28)

1. Chen Y, Takita J, Choi YL et al (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455:971-974.
2. Choi YL, Takeuchi K, Soda M et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68:4971-4976.
3. Christensen JG, Zou HY, Arango ME et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6:3314.
4. Fukuyoshi Y, Inoue H, Kita Y et al (2008) EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer 98:1536-1539.
5. Galkin AV, Melnick JS, Kim S et al (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 104:270-275.
6. George RE, Sanda T, Hanna M et al (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978.
7. Grob TJ, Heilenkötter U, Geist S et al (2012) Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res Treat 134:561-567.
8. Iwahara T, Fujimoto J, Wen D et al (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14:439-449.
9. Janoueix-Lerosey I, Lequin D, Brugières L et al (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455:967-970.
10. Koivunen JP, Mermel C, Zejnullahu K et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275-4283.
11. Lawrence B, Perez-Atayde A, Hibbard MK et al (2000) TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 157:377-384.
12. Lin E, Li L, Guan Y, Soriano R et al (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7:1466-1476.
13. Mano H (2008) Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci 99:2349-2355.
14. McDermott U, Iafrate AJ, Gray NS et al (2008) Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68:3389-3395.
15. Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281-1284.
16. Morris SW, Naeve C, Mathew P et al (1997) ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14:2175-2188.
17. Mossé YP, Laudenslager M, Longo L et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930-935.
18. Pulford K, Lamant L, Morris SW et al (1997) Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89:1394-1404.
19. Pulford K, Morris SW, Turturro F (2004) Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199:330-358.
20. Robertson FM, Petricoin EF, Chu K et al (2011) Amplification of anaplastic lymphoma kinase (ALK) as a common genetic alteration in inflammatory breast cancer. CTRC-AACR San Antonio breast cancer symposium, tumor cell biology: novel/emerging therapeutic targets. P3:01-18.
21. Shiota M, Fujimoto J, Takenaga M et al (1994) Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 84:3648-3652.
22. Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566.
23. Soda M, Takada S, Takeuchi K et al (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 105:19893-19897.
24. Takeuchi K, Choi YL, Soda M et al (2008) Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14:6618-6624.
25. Takeuchi K, Choi YL, Togashi Y et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALKpositive lung cancer. Clin Cancer Res 15:3143-3149.
26. Tuma RS (2012) ALK gene amplified in most inflammatory breast cancers. J Natl Cancer Inst 104:87-88.
27. Wan W, Albom MS, Lu L et al (2006) Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 107:1617-1623.
28. Wong DW, Leung EL, So KK, University of Hong Kong Lung Cancer Study Group et al (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115:1723-1733.